Multicenter phase 1 study of fast off-rate CD19 CAR-T therapy for relapsed or refractory B-cell ALL

The role of CD19CAR-T in relapsed or refractory adult B-cell ALL is not established, with clinical studies showing significant toxicity and frequent requirement for allogeneic stem-cell transplantation consolidation. The multicenter phase 1 ALLCAR study in the UK evaluated a novel CD19CAR (AUTO1) with a rapid-binding off rate for CD19, designed to reduce toxicity and improve persistence in patients with R/R B-ALL. AUTO1 had a tolerable safety profile, and resulted in high remission rates (85% MRD-negative complete response at one month) and excellent persistence.